Nuvation Bio (NUVB) Share-based Compensation (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Share-based Compensation of $109000.0 for Q1 2026, down 98.61% year-over-year from $7.9 million in Q1 2025, and down 98.64% quarter-over-quarter from $8.0 million in Q4 2025.
Nuvation Bio (NUVB) Share-based Compensation (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Share-based Compensation for 7 consecutive years, with $109000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 98.61% year-over-year to $109000.0; the TTM figure through Mar 2026 stood at $28.1 million (down 19.78% YoY), while the FY2025 annual figure was $51.3 million, up 5.99% from the prior year.
- Share-based Compensation eased to $109000.0 in Q1 2026 per NUVB's latest filing, from $8.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $12.0 million in Q2 2025 and bottomed at -$9.1 million in Q4 2022.
- Historically, Share-based Compensation has averaged $5.4 million across 5 years, with a median of $5.5 million in 2023.
- On a YoY basis, Share-based Compensation climbed as much as 128.42% in 2022 and fell as far as 426.18% in 2022.
- Nuvation Bio's Share-based Compensation stood at -$9.1 million in 2022, then surged by 159.47% to $5.4 million in 2023, then jumped by 87.61% to $10.2 million in 2024, then fell by 21.6% to $8.0 million in 2025, then sank by 98.64% to $109000.0 in 2026.
- Business Quant data shows NUVB's Share-based Compensation at $109000.0 in Q1 2026, $8.0 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 10.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.46 Mn |
| Jun 30, 2026 | 10.46 Mn |
| Mar 31, 2026 | 109,000.00 |
| Mar 31, 2026 | 109,000.00 |
| Dec 31, 2025 | 7.99 Mn |
| Dec 31, 2025 | 7.99 Mn |
| Sep 30, 2025 | 8.02 Mn |
| Sep 30, 2025 | 8.02 Mn |
| Jun 30, 2025 | 12.03 Mn |
| Jun 30, 2025 | 12.03 Mn |
| Mar 31, 2025 | 7.85 Mn |
| Mar 31, 2025 | 7.85 Mn |
| Dec 31, 2024 | 10.19 Mn |
| Dec 31, 2024 | 10.19 Mn |
| Sep 30, 2024 | 7.48 Mn |
| Sep 30, 2024 | 7.48 Mn |
| Jun 30, 2024 | 9.57 Mn |
| Jun 30, 2024 | 9.57 Mn |
| Sep 30, 2023 | 5.43 Mn |
| Sep 30, 2023 | 5.43 Mn |